



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)
A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2020/064461

(22) International Filing Date:

11 December 2020 (11.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/947,455 12 December 2019 (12.12.2019) US

(71) Applicant: **ALECTOR LLC** [US/US]; 131 Oyster Point Blvd, Suite 600, South San Francisco, California 94080 (US).

(72) Inventors: **PAUL, Robert**; c/o Alector LLC, 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080 (US). **WARD, Michael F.**; c/o Alector LLC, 131 Oyster Point Boulevard, Suite 600, South San Fran-

cisco, California 94080 (US). **LONG, Hua**; c/o Alector LLC, 131 Oyster Point Blvd., Suite 600, South San Francisco, California 94080 (US). **LU, Shiao-Ping**; c/o Alector LLC, 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080 (US). **SIDDIQUI, Omer Rizwan**; c/o Alector LLC, 131 Oyster Point Boulevard, Suite 600, South San Francisco, California 94080 (US). **ROSENTHAL, Arnon**; c/o Alector LLC, 131 Oyster Point Blvd., Suite 600, South San Francisco, California 94080 (US).

(74) Agent: **TSAO, Patricia**; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: METHODS OF USE OF ANTI-CD33 ANTIBODIES




FIG. 1

(57) Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics. The present disclosure is further directed to the methods of treating and/or delaying the progression of a disease or injury in an individual by administering such antibodies.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*